Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 4/20 | 0.44 |
| ▸ | LAP3 | P28838 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4663283 | 0.81 | FFAR1 (0.46) | FFAR1FFAR4LTA4HLAP3PPARG | |
| SCHEMBL4663289 | 0.81 | FFAR1 (0.46) | FFAR1FFAR4LTA4HLAP3PPARG | |
| SCHEMBL4663286 | 0.81 | FFAR1 (0.46) | FFAR1FFAR4LTA4HLAP3PPARG | |
| SCHEMBL6029233 | 0.74 | FFAR1 (0.47) | FFAR1FFAR4LTA4HLAP3PPARG | |
| SCHEMBL659105 | 0.72 | SLC7A5 (0.69) | FFAR1FFAR4LTA4HLAP3PPARG | |
| SCHEMBL515522 | 0.72 | SLC7A5 (0.69) | FFAR1FFAR4LTA4HLAP3PPARG | |
| SCHEMBL288912 | 0.72 | SLC7A5 (0.69) | FFAR1FFAR4LTA4HLAP3PPARG | |
| SCHEMBL17738622 | 0.71 | LTA4H (0.64) | FFAR1FFAR4LTA4HLAP3PPARG | |
| SCHEMBL18025356 | 0.71 | LTA4H (0.64) | FFAR1FFAR4LTA4HLAP3PPARG | |
| SCHEMBL14559932 | 0.71 | LTA4H (0.64) | FFAR1FFAR4LTA4HLAP3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | claimed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | claimed |
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | disclosed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | BACE1, PSEN1, BACE2 | FFAR1 601/4885FFAR4 1654/4885LTA4H 1086/4885 |
| US-20050119329-A1 | Tetronic and tetramic acids | BACE1, PSEN1, BACE2 | FFAR1 601/4885FFAR4 1654/4885LTA4H 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.